← Research index · Disorder page · Source YAML

Cross-provider research synthesis

Arterial Calcification of Infancy

MONDO:0018870 Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 34 citations openscientist · 47 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Generalized Arterial Calcification of Infancy (GACI) is an autosomal recessive ectopic-mineralization disorder caused by biallelic loss-of-function variants in ENPP1 (the majority of cases) or, less often, ABCC6, both converging on systemic deficiency of inorganic pyrophosphate (PPi).

UNANIMOUS INTEGRATED

genetic_factorpathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	ENPP1 accounts for ~67% to ~75% of reported cases, while ABCC6 accounts for ~9% to ~10%; ENPP1 is the predominant cause, with ABCC6 representing a smaller but important overlapping subtype Falcon gives the ENPP1-majority / ABCC6-minority split and identifies the two genes, framing them as one low-PPi pathway.
openscientist	CONCORDANT	90%	accounts for the majority of GACI cases. ENPP1 hydrolyzes extracellular ATP to generate AMP and inorganic pyrophosphate (PPi). OpenScientist agrees ENPP1 accounts for the majority of cases; it quantifies the split slightly differently (ENPP1 ~85%, ABCC6 ~15%) than Falcon (~67-75% / ~9-10%), a dataset-dependent numeric difference rather than a contradiction. PMID:12881724, PMID:32172442

ENPP1 hydrolyzes extracellular ATP into AMP and inorganic pyrophosphate (PPi), and PPi is the principal endogenous inhibitor of hydroxyapatite crystal deposition; loss of ENPP1 function lowers PPi and permits ectopic arterial calcification.

UNANIMOUS INTEGRATED

pathophysiologygene_function

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	Generalized arterial calcification of infancy (GACI) is a rare, life-threatening disorder caused by loss-of-function mutations in the gene encoding ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), which normally hydrolyzes extracellular ATP into AMP and pyrophosphate (PPi). Falcon quotes the canonical enzymatic definition (ATP to AMP + PPi) as the mechanistic basis of the disorder. DOI:10.1242/dmm.035691
openscientist	CONCORDANT	95%	ENPP1 generates PPi from ATP. PPi is the principal endogenous inhibitor of hydroxyapatite crystal deposition. In GACI, PPi deficiency allows spontaneous calcium-phosphate precipitation in arterial walls. OpenScientist states the same PPi-as-hydroxyapatite-inhibitor mechanism and the consequence of its deficiency.

Beyond loss of the anti-calcification PPi arm, reduced ENPP1-derived AMP/adenosine signaling is a second disease driver, promoting vascular smooth muscle cell (myointimal/neointimal) proliferation and arterial stenosis.

UNANIMOUS INTEGRATED

pathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	reduced AMP/adenosine signaling may also contribute to intimal proliferation and stenosis Falcon names the AMP/adenosine branch as an additional driver of intimal proliferation and stenosis beyond calcification.
openscientist	CONCORDANT	85%	Adenosine inhibits vascular smooth muscle cell (VSMC) proliferation and suppresses TNAP synthesis. Loss of this pathway contributes to neointimal hyperplasia OpenScientist details the adenosine-VSMC axis and attributes neointimal hyperplasia to its loss, matching Falcon's second-driver framing. PMID:30369595

GACI presents in the fetal or neonatal period with diffuse calcification and stenosis of large and medium arteries, producing severe hypertension, heart failure, and prenatal manifestations (hydrops fetalis, polyhydramnios, echogenic vasculature).

UNANIMOUS INTEGRATED

phenotype

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	and associated intimal proliferation/stenosis of large and medium arteries, producing severe neonatal/infant cardiovascular compromise (e.g., hypertension, heart failure, ischemia). Falcon describes calcification/stenosis of large-medium arteries with neonatal hypertension, heart failure, and ischemia; elsewhere it lists prenatal hydrops and polyhydramnios.
openscientist	CONCORDANT	90%	It is characterized by diffuse calcification of the internal elastic lamina and fibrointimal proliferation of large and medium-sized muscular arteries, including the aorta, coronary arteries, renal arteries, and pulmonary arteries. The disease typically presents in the fetal or neonatal period with heart failure, severe hypertension, and respiratory distress. OpenScientist gives the same arterial distribution and the neonatal heart-failure / hypertension presentation.

Prognosis in infancy is poor, with overall mortality around 54.7% and a 50.4% probability of death before 6 months; mortality is significantly higher in ENPP1 than ABCC6 deficiency (40.5% vs 10.5%).

UNANIMOUS INTEGRATED

prognosisepidemiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	overall mortality 54.7% in a 247-record natural history cohort, including 13.4% in utero/stillborn, with a 50.4% probability of death before 6 months Falcon reports the same natural-history mortality figures (54.7% overall, 50.4% before 6 months) and elsewhere the 40.5% vs 10.5% ENPP1-vs-ABCC6 difference. DOI:10.1002/jbmr.4418
openscientist	CONCORDANT	95%	Overall mortality was 54.7% (13.4% in utero or stillborn), with a 50.4% probability of death before the age of 6 months (critical period). OpenScientist quotes the identical natural-history mortality statistics from the same 247-patient cohort. PMID:34355424

Survivors of the acute infantile phase evolve a lifelong multisystem disease, especially in ENPP1 deficiency: FGF23-mediated hypophosphatemic rickets (ARHR2), sensorineural hearing loss (~75% lifetime risk), cervical spine fusion (~25%), and enthesis calcification as the main adult morbidity.

UNANIMOUS INTEGRATED

phenotypeprognosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	ENPP1-deficient survivors also showed elevated FGF23, hearing loss risk ~75%, and cervical spine fusion risk ~25% Falcon lists the survivor spectrum (elevated FGF23, ~75% hearing loss, ~25% cervical spine fusion, rickets, enthesis calcification).
openscientist	CONCORDANT	90%	For ENPP1-deficient individuals, the lifetime risk of cervical spine fusion was 25%, that of hearing loss was 75%, and the main morbidity in adults was related to enthesis calcification OpenScientist quotes the prospective survivor cohort with the same 25% / 75% risks and enthesis calcification as adult morbidity, plus FGF23-driven rickets. PMID:33005041

ENPP1-Fc enzyme replacement therapy (INZ-701) is the leading disease-targeted strategy, restoring circulating PPi and preventing calcification (eliminating mortality in ENPP1-deficient mouse models), and has advanced into clinical trials.

UNANIMOUS INTEGRATED

treatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	A 2023 expert therapeutic review positions ENPP1 replacement as a leading strategy, supported by preclinical benefits on calcification and cardiovascular function in ENPP1-deficient mice and normalization of biomarkers Falcon frames ENPP1 replacement (INZ-701) as the leading strategy with preclinical benefit, and separately catalogs the ENERGY/ADAPT clinical-trial records. DOI:10.3389/fddsv.2023.1249966
openscientist	CONCORDANT	90%	INZ-701, a human ENPP1-Fc protein, is in clinical development as an enzyme replacement therapy for the treatment of ENPP1 deficiency OpenScientist identifies INZ-701 ENPP1-Fc as the ERT in clinical development and notes it eliminates mortality in the murine model. PMID:33900645

Bisphosphonates (PPi analogs such as etidronate and pamidronate) have long been used off-label, but the largest natural-history study found no survival benefit on a start-time matched analysis.

UNANIMOUS INTEGRATED

treatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Bisphosphonates (e.g., etidronate, pamidronate, zoledronic acid) are used off-label, but evidence is inconsistent and no standard regimen exists; one natural history study found no survival benefit in start-time matched analyses. Falcon reports off-label bisphosphonate use and the no-survival-benefit finding from the matched natural-history analysis. DOI:10.1002/jbmr.4418
openscientist	CONCORDANT	90%	Contrary to previous publications, we found that bisphosphonate treatment had no survival benefit based on a start-time matched analysis and inconclusive results when initiated within 2 weeks of birth OpenScientist quotes the same cohort's conclusion that bisphosphonates confer no start-time-matched survival benefit. PMID:34355424

ENPP1 has a broader, non-cardiovascular biology — it is the dominant hydrolase of the STING agonist 2'3'-cGAMP (an innate immune checkpoint) and a bidirectional calcification regulator, with gain-of-expression linked to CPPD/chondrocalcinosis.

SINGLE LEAD

gene_functioncomorbidity

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	85%	ENPP1 is the dominant hydrolase of extracellular 2'3'-cGAMP, a STING agonist. This role makes ENPP1 an innate immune checkpoint OpenScientist develops the cGAMP-STING immune-checkpoint role and the bidirectional calcification (GACI vs CPPD) framing at length; retained as a lead beyond core GACI pathophysiology. PMID:37333273
falcon	SILENT	—	Falcon's ectopic-calcification-focused report does not address the ENPP1 cGAMP-STING immune-checkpoint role or the bidirectional CPPD/chondrocalcinosis association.

Narrative

Overview

Both providers frame Arterial Calcification of Infancy as Generalized Arterial Calcification of Infancy (GACI), an ultra-rare autosomal recessive ectopic-mineralization disorder in which biallelic loss of ENPP1 (majority) or ABCC6 (minority) causes systemic inorganic pyrophosphate (PPi) deficiency, driving hydroxyapatite deposition and stenosis of large and medium arteries with high early mortality and, in survivors, an evolving lifelong ENPP1-deficiency spectrum.

Agreement

The reports converge tightly on the core biology: ENPP1 hydrolyzes extracellular ATP to AMP + PPi; PPi is the principal inhibitor of hydroxyapatite crystal growth; and a second AMP/adenosine arm restrains vascular smooth muscle cell proliferation, so its loss adds intimal/neointimal proliferation and stenosis. They agree on the clinical picture (fetal/neonatal arterial calcification, severe hypertension, heart failure, prenatal hydrops/polyhydramnios), on the natural-history mortality (54.7% overall, 50.4% before 6 months, higher in ENPP1 than ABCC6), on the survivor spectrum (FGF23-mediated hypophosphatemic rickets/ARHR2, ~75% hearing loss, ~25% cervical spine fusion, enthesis calcification), on ENPP1-Fc/INZ-701 enzyme replacement as the leading disease-targeted therapy, and on the finding that bisphosphonates confer no matched survival benefit.

Divergence

Divergence is largely coverage and emphasis rather than contradiction. Falcon emphasized clinical-trial provenance for INZ-701 (ENERGY, ENERGY 2, ENERGY 3, ADAPT records) and the gene-proportion split framed as ~67-75% ENPP1 / ~9-10% ABCC6. OpenScientist provided a broader mechanistic and translational review, including a slightly different proportion estimate (~85% / ~15%), ENPP1 crystal structures, the FGF23 "mineralization paradox," and two threads Falcon does not cover at all: ENPP1 as an innate immune checkpoint via cGAMP-STING hydrolysis, and ENPP1 as a bidirectional calcification regulator (loss-of- function GACI vs gain-of-expression CPPD/chondrocalcinosis). The only numeric differences (gene-proportion estimates) are dataset-dependent, not conflicting.

Integration

Integrated into kb/disorders/Arterial_Calcification_of_Infancy.yaml: the ENPP1/ABCC6 PPi-deficiency mechanism with the AMP/adenosine second-driver arm; the arterial phenotype and prenatal presentation; the natural-history mortality and ENPP1-vs-ABCC6 outcome difference; the survivor spectrum (FGF23/ARHR2, hearing loss, cervical spine fusion, enthesopathy); ENPP1-Fc/INZ-701 enzyme replacement as the leading therapy with the clinical-trial records; and the bisphosphonate no-survival-benefit update.

Not integrated (leads)

Retained as research leads rather than promoted: the ENPP1 cGAMP-STING immune-checkpoint role and bidirectional CPPD/chondrocalcinosis association, speculative TNAP-inhibition and nanoparticle/chelator anti-calcification strategies, allele-specific 4-PBA chaperone rescue of ABCC6 mutants, expanded genotype-specific variant lists, and detailed prenatal ultrasound findings.

Cross-provider synthesis comparing the falcon (ectopic-calcification / clinical-trial-focused) and openscientist (comprehensive, 15-domain) reports. No direct contradictions were found; divergence is coverage/emphasis plus a minor dataset-dependent difference in the ENPP1/ABCC6 case-proportion estimates. All best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally left to the main curation pipeline on the disorder YAML.